Delcath Systems (DCTH) Stock Analysis & Winston Score

Delcath Systems is a small medical device company that makes a specialized system for delivering high doses of chemotherapy directly to the liver. Its main product is called HEPZATO KIT (melphalan hydrochloride for injection), which is used to treat a rare form of eye cancer called uveal melanoma that has spread to the liver. The company sells to hospitals and cancer treatment centers in the United States, where HEPZATO received FDA approval in 2023. Delcath earns revenue by selling its HEPZATO KIT system to hospitals on a per-procedure basis, meaning it gets paid each time the treatment is used on a patient. The company is small, with a market cap around $400 million, and currently operates primarily in the US while pursuing regulatory approvals in Europe under the name CHEMOSAT. Its high gross margin reflects the premium pricing of a niche, FDA-approved oncology device, but the key risk is that the addressable patient population for uveal melanoma liver metastases is very small, which limits how large the business can grow.